|本期目录/Table of Contents|

[1]钱涛涛,施舜缤,朱 勇,等.Th17细胞相关因子在早晚期肺癌患者中的表达差异及临床意义[J].中华肺部疾病杂志,2020,(03):350-354.[doi:10.3877/cma.j.issn.1674-6902.2020.03.012]
　Huang Dongmei,Liu Jun,Li Fuxiang,et al.Related risk factors of carbapenem-resistant Acinetobacter baumannii in second-level general hospitals of Sichuan province[J].,2020,(03):350-354.[doi:10.3877/cma.j.issn.1674-6902.2020.03.012]
点击复制

Th17细胞相关因子在早晚期肺癌患者中的表达差异及临床意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
350-354
栏目:
论著
出版日期:
2020-06-20

文章信息/Info

Title:
Related risk factors of carbapenem-resistant Acinetobacter baumannii in second-level general hospitals of Sichuan province
作者:
钱涛涛; 施舜缤; 朱 勇; 张 林; 王海龙
215200 苏州,苏州市第九人民医院胸外科
Author(s):
Huang Dongmei1;  Liu Jun1;  Li Fuxiang2;  Fan Li3;  Jing Yingjie4;  and Xiao Peng5.
1Department of Respiratory Medicine, Jintang First people's Hospital, Jintang County 610400, Sichuan Province, China; 2Department of Respiratory Medicine, General Hospital of Western Theater Command, Chengdu 610083, China; 3Xindu District People's Hospital of Chengdu, Chengdu 610500, China; 4People's Hospital of Nanbu, Nanchong 637300, Sichuan Province, China; 5People's Hospital of Lezhi, Lezhi 641500, Sichuan Province, China
关键词:
支气管肺癌;  早期;  晚期;  Th17细胞;  相关因子;  表达差异
Keywords:
Second-level general hospital;  Acinetobacter baumannii;  Carbapenem-resistant;  Drug resistance;  Risk factors
分类号:
R563,R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.012
摘要:
目的 探讨四川省二级综合医疗机构耐碳青霉烯类鲍曼不动杆菌(carbapenem-resistant acinetobacter baumannii, CRAB)的耐药情况及相关临床危险因素。方法 采取回顾性病例-对照研究方法,调查2015年1月至2016年1月四川地区6家二级甲等综合医院鲍曼不动杆菌感染患者病例,根据药敏结果分为CRAB组和碳青霉烯敏感组(CSAB)。结果 共收集到非重复Ab菌株202株,其中CRAB 90株,耐药率40.1%。CRAB发生的4个独立危险因素为留置尿管(OR=9.576,95%CI:4.964～18.474,P=0.000)、中央静脉置管(OR=2.707,95%CI:1.158～6.330,P=0.022)、氟喹诺酮类(OR=3.869,95%CI:1.603～9.377,P=0.003)及碳青霉烯类抗菌药物(OR=2.755,95%CI:1.164～6.521,P=0.021)的使用。结论 二级综合医院CRAB感染的发生与侵袭性操作、氟喹诺酮类及碳青霉烯类等抗菌药物的选择压力有关。
Abstract:
Objective To explore the related risk factors of carbapenem-resistant Acinetobacter baumannii in second-level general hospitals of Sichuan province. Methods A retrospective case-control study was performed, and the patients with Acinetobacter baumannii infection in the 6 second-level comprehensive hospitals in Sichuan province from January 2015 to January 2016 were selected for this study. According to the drug sensitivity results, the patients were divided into a carbapenem-resistant Acinetobacter baumannii(CRAB)group and a carbapenem-sensitive Acinetobacter baumannii(CSAB)group. Results A total of 202 strains of non-repeated Acinetobacter baumannii were collected, among which 90 strains were resistant to carbapenem. The resistance rate of Acinetobacter baumannii to carbapenem was 40.1%. There were four independent risk factors for CRAB infections: urinary catheterization(OR=9.576, 95%CI=4.964～18.474, P=0.000), central venous catheterization(OR=2.707, 95%CI=1.158～6.330, P=0.022), the use of fluoroquinolone(OR=3.869, 95%CI=1.603～9.377, P=0.003), and the application of carbapenem antibiotics(OR=2.755, 95%CI=1.164～6.521, P=0.021). Conclusion CRAB occurrence may be related with the invasive procedure and the selection pressure of fluoroquinolone and carbapenem antibiotics in second-level comprehensive hospitals.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 任成山, 白 莉, 钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
3 李晓英, 方 文, 杨 梅, 等. NSCLC患者外周血中MAGE-D4抗体的表达及意义[J]. 贵州医药, 2018, 42(12): 1420-1421.
4 Fernández-Somoano A, álvarez-Avellón SM, Souto-García A, et al. Alcohol Consumption and Lung Cancer According to Ile349Val Polymorphism in ADH3 Gene: Beyond the Tobacco Smoking Effect[J]. J Cancer, 2017, 8(12): 2296-2302.
5 陈婧华, 钟文昭, 吴一龙. 2017年NSCLC靶向治疗进展[J]. 循证医学, 2018, 18(1): 3-5.
6 袁海洪. 肺癌的遗传学及分子改变研究近况概述[J]. 医学信息, 2015, 11(23): 314-315.
7 Sang-sang Ren, Jing-wen Deng, Meng Hong, et al. Ethical considerations of cellular immunotherapy for cancer[J]. Journal of Zhejiang University Scince B, 2019, 20(1): DOI: 10.1631/jzus.B1800421.
8 张静文, 杨紫潇, 徐 旸, 等. 特异性T细胞免疫治疗脑胶质瘤模型的研究[J]. 中华实验外科杂志, 2018, 35(12): 2281-2283.
9 Marshall EA, Ng KW, Kung SHK, et al. Emerging roles of T helper 17 and regulatory T cells in lungcancer progression and metastasis[J]. Mol cancer, 2016, 15(1): 67-67.
10 Oh K, Seo MW, Kim YW, et al. Osteopontin Potentiates Pulmonary Inflammation and Fibrosis by Modulating IL-17/IFN-γ-secreting T-cell Ratios in Bleomycin-treated Mice[J]. Immune Netw, 2015, 15(3): 142-149.
11 石宝玉, 周 灵, 朱海星, 等. IL-17A通过增强肿瘤血管生成和侵袭促进肿瘤发展[J]. 国际呼吸杂志, 2014,(14): 1075-1080.
12 Punt S, Fleuren GJ, Kritikou E, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer[J]. Oncoimmunology, 2015, 4(1): e984539.
13 Leone FT, Everscasey S, Toll BA, et al. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e1S-29s.
14 陈万青, 李 贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13.
15 Chen WQ, Sun KX, Zheng RS. Report of Cancer Incidence and Mortality in Different Areas of China, 2014[J]. China Cancer, 2018, 27(1): 1-14.
16 张 力. NSCLC的免疫治疗新进展[J]. 医学与哲学: 临床决策论坛版, 2015, 36(2): 13-17.
17 杨 林, 赵晓红, 杨云梅. NSCLC治疗的新进展[J/CD]. 中华危重症医学杂志(电子版), 2017, 10(6): 416-420.
18 韦腾飞, 张 军, 吴 豫, 等. CD4+ T细胞表面共抑制分子的表达水平与NSCLC疾病进展的关系[J]. 中华肿瘤杂志, 2014, 36(6): 424-429.
19 Cornelia Voigt, Peter May, Adrian Gottschlich, et al. Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth[J]. Proc Natl Acad Sci USA, 2017, 114(49): 201705165.
20 Liu CY, Xie WG, Wu S, et al. A comparative study on inflammatory factors and immune functions of lung cancer and pulmonary ground-glass attenuation[J]. Eur Rev Med Pharmacol Sci, 2017, 21(18): 4098-4103.
21 刘爱民. NSCLC患者外周血中辅助性T细胞17与调节性T淋巴细胞平衡变化的研究[J]. 河北医药, 2017, 39(8): 1225-1227.
22 Robinson KM, Manni ML, Biswas PS, et al. Clinical Consequences of Targeting IL-17 and TH17 in Autoimmune and Allergic Disorders[J]. Curr Allergy Asthm R, 2013, 13(6): 587-595.
23 Sha L, Yan L, Xun Q, et al. Detection and significance of TregFoxP3+ and Th17 cells in peripheral blood of non-small cell lung cancer patients[J]. Arch Med Sci, 2014, 2: 232-239.
24 Duan MC, Han W, Jin PW, et al. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer[J]. Inflammation, 2015, 38(6): 2156-2165.
25 Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications[J]. Lung Cancer, 2013, 82(2): 179-189.
26 范恒建, 张玉可, 肖 伟, 等. 肺腺癌患者外周血Treg和Th17细胞的变化及其对预后的影响[J]. 山东大学学报(医学版), 2012, 50(9): 73-78.
27 耿婉如, 高峨嵋, 贺航咏. Th17细胞对肺癌双向调节作用的研究进展[J]. 细胞与分子免疫学杂志, 2017, 33(4): 550-554.
28 Ma QY, Chen J, Wang SH, et al. Interleukin 17A genetic variations and susceptibility to non-small cell lung cancer[J]. Apmis, 2015, 123(3): 194-198.
29 王 胜, 张 蕊, 王俊凤, 等. Th17细胞及IL-17在NSCLC患者外周血的表达及临床意义[J]. 实用临床医药杂志, 2015, 19(23): 34-36.
30 李必一, 王若雨, 赵 勇. IL-17在肿瘤发生发展中的作用及其临床意义[J]. 中国医药生物技术, 2016, V12(1): 64-68.
31 但卫斌, 黄小芳, 吴大和, 等. 60例NSCLC中IL-21R、MMP-2的表达及意义[J]. 肿瘤学杂志, 2017, 23(7): 610-614.
32 刘 晶, 李珊珊, 梁海龙, 等. NSCLC患者血清IL-17和IL-21水平变化及临床意义[J]. 标记免疫分析与临床, 2017, 24(9): 29-31.

备注/Memo

备注/Memo:
基金项目: 苏州市吴江区科学技术局(WS201313)
更新日期/Last Update: 2020-06-20